Use of QSPR Modeling to Characterize In Vitro Binding of Drugs to a Gut-Restricted Polymer

Christine Taylor Brew¹ • James F. Blake² • Anita Mistry¹ • Fengling Liu¹ • Diana Carreno¹ • Deidre Madsen¹ • YongQi Mu¹ • Martha Mayo³ • Wilhelm Stahl⁴ • David Matthews¹ • Derek Maclean¹ • Steve Harrison¹

Received: 13 December 2017 / Accepted: 27 January 2018 / Published online: 8 March 2018 © The Author(s) 2018. This article is an open access publication

ABSTRACT

Purpose Polymeric drugs, including patiromer (Veltassa®), bind target molecules or ions in the gut, allowing fecal elimination. Non-absorbed insoluble polymers, like patiromer, avoid common systemic drug-drug interactions (DDIs). However, the potential for DDI via polymer binding to orally administered drugs during transit of the gastrointestinal tract remains. Here we elucidate the properties correlated with drug-patiromer binding using quantitative structure-property relationship (QSPR) models.

Methods We selected 28 drugs to evaluate for binding to patiromer in vitro over a range of pH and ionic conditions intended to mimic the gut environment. Using this in vitro data, we developed QSPR models using step-wise linear regression and analyzed over 100 physiochemical drug descriptors.

Results Four descriptors emerged that account for ~70% of patiromer-drug binding in vitro: the computed surface area of hydrogen bond accepting atoms, ionization potential, electron affinity, and lipophilicity ($R^2 = 0.7$, $Q^2 = 0.6$). Further, certain molecular properties are shared by nonbinding, weak, or strong binding compounds.

Conclusions These findings offer insight into drivers of in vitro binding to patiromer and describe a useful approach for assessing potential drug-binding risk of investigational polymeric drugs.

KEY WORDS drug interaction · electron affinity · hydrogen bonding · ionization potential · lipophilicity

ABBREVIATIONS

| Abbreviation | Definition |
|--------------|------------|
| AB           | Acetate buffer |
| AUC          | Area under the curve |
| BCS          | Biopharmaceutics Classification System |
| CI           | Confidence interval |
| Conc         | Concentration |
| CV           | Cross-validation |
| DDI          | Drug-drug interaction |
| HCl          | Hydrochloride |
| IRev,PM3     | Calculated ionization potential |
| LogD         | Lipophilicity |
| LogP         | Partition coefficient |
| PK           | Pharmacokinetics |
| QPlogPw,QikProp | Predicted water gas partition coefficient |
| QSPR         | Quantitative structure-property relationship |
| SAA1         | Sum of surface area on acceptor atoms |
| SGF          | Simulated gastric fluid |
| SIF          | Simulated intestinal fluid |
| Xamide       | Number of non-conjugated amide groups |
| X.noncon     | Number of ring atoms not able to form conjugated aromatic systems |

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11095-018-2356-y) contains supplementary material, which is available to authorized users.
INTRODUCTION

Large polymer drugs typically have a high density of binding sites and thus a large capacity to absorb their target species (1). As large insoluble particles (>10 μm), they are excreted, along with the bound material, rather than being digested and absorbed into the blood stream. This has the advantage of reducing the potential for systemic off-target effects or drug-drug interactions (DDIs), such as cytochrome P450 enzyme inhibition. However, the potential for DDIs during transit of the gastrointestinal tract remains.

Veltassa® (patiromer; Relypsa, Inc., a Vifor Pharma Group Company; Redwood City, CA) is a non-absorbed, potassium binding drug approved for the treatment of hyperkalemia (elevated serum potassium). The active ingredient is patiromer sorbitex calcium which consists of the active moiety, patiromer, a cross-linked anionic polymer, and a calcium sorbitol counter-ion (Fig. 1) (2). It is formulated as a powder that is mixed with water and given orally, once daily at a starting dose of 8.4 g. Patiromer binds potassium in the gastrointestinal tract, particularly the colon. Results of an in vitro study showed that patiromer has a binding capacity of 8.5–8.8 mEq of potassium per gram of polymer (3). Patiromer, along with bound potassium, is eliminated in the feces, reducing serum potassium levels (3).

In addition to binding potassium during transit of the gut, there is the potential for negatively charged patiromer to bind to co-administered oral drugs, particularly those that are positively charged or that bind its counter-ion, calcium. It is important to understand the clinical potential for patiromer-drug interactions, as patients with hyperkalemia typically suffer from chronic disease, notably chronic kidney disease, heart failure, and diabetes, and may have multiple comorbid conditions.

As previously reported, compounds tested for DDIs in human subjects were prescreened for the ability to bind patiromer in vitro (4). Significant binding to patiromer (>30% of drug bound) was observed with 14 of the 28 small molecule drugs assessed and this formed the basis for compound selection in the clinical studies. In this clinical testing, 3 of the 12 compounds tested showed a potential for clinically relevant DDIs when administered together with patiromer; however, no clinically meaningful DDIs were observed when the drugs were given 3 h apart (4).

Of necessity, clinical DDI studies are incomplete, as only a subset of drugs that might be co-administered can be tested. A limited literature exists on polymer DDIs; however, the unique engineered properties of each polymer make it unlikely that findings with one can be generalized to another. Rather, in vitro assays and in silico modeling can be used to help predict those compounds most or least likely to bind a given polymer. For example, Walker and colleagues (5) reported the development of a quantitative structure-property relationship (QSPR) model describing binding in vitro to the polymer bile acid sequestrant, colesevelam hydrochloride. Using partial least-squares regression analysis, drug lipophilicity emerged as the primary determinant of colesevelam-drug binding. The authors also went on to show that in vitro binding sensitively identified compounds with a low probability of causing a clinically significant DDI in vivo (5).

Here we report the development of QSPR models of patiromer-drug binding in vitro based on step-wise linear regression analysis of over 100 measured and calculated drug properties and in vitro binding data (4). We identify the physicochemical characteristics of drugs that best predict binding to patiromer in vitro, as well as the molecular properties of drugs with strong, weak, or no binding to patiromer. The QSPR models reported here illustrate the utility of an in silico approach to evaluate the potential for drugs to bind polymeric drugs.

MATERIALS AND METHODS

Test Articles

Patiromer

Patiromer sorbitex calcium is manufactured by Relypsa, Inc., under good manufacturing practices.

Drugs

All test drugs were obtained from US Pharmacopeia (Rockville, MD), except rivaroxaban, cinacalcet hydrochloride (TRC; North York, ON, Canada) and apixaban (Alsachim; Strasbourg, France).
**pKa, LogP and LogD Determination**

Test drug properties pKa, LogP, and LogD, as shown in Table I, were experimentally determined as follows.

**pKa**

Test drug pKas were determined experimentally by titration in aqueous solution. Ionization state was monitored by UV or pH. Reported values are the average of three independent determinations. For drugs with poor aqueous solubility, which required a co-solvent (25 to 50%), pKa was determined by Yasuda-Shedlovsky extrapolation. Drug concentration was in the range 17–31 μM (UV) or ≥0.4 mM (pH).

**logP**

Compound logPs were determined by titration in various ratios of octanol and water at concentrations no lower than 0.4 mM. The shift of the aqueous pKas in the presence of octanol was used to determine the logP of the different species.

**logD(7.4)**

The logD of the sample was determined at pH 7.4 by liquid-liquid distribution chromatography. Compounds were eluted from an octanol-coated column with an octanol-saturated mobile phase adjusted to pH 7.4. Compound retention time was converted to logD value by comparison to the retention time of a set of standard compounds with well-characterized logD octanol values.

**In Vitro Binding Assays**

Patiromer binding to test compounds was assessed by comparing free test drug concentrations after incubation with and without patiromer. Patiromer anion was added to a concentration of 25.2 g/L, representing a maximal patiromer dose dispersed in the approximate volume of fluid in the upper adult gastrointestinal tract (1 L) (6). Test drug concentrations were based on the lowest clinically relevant dose of test drug in US prescribing information in a 1-L volume. Test drug stock solutions were prepared at 5 mg/mL (6 mg/mL for lithium carbonate) in either dimethyl sulfoxide or Milli-Q water and diluted to the final desired concentration in test media. Drugs that were not soluble at concentrations equivalent to the lowest prescribed dose (ciprofloxacin, furosemide, phenytoin) were used at the maximum achievable concentration (see Table I for final values).

Three test buffers were used: simulated gastric fluid without added pepsin (SGF; initial pH 1.2), acetate buffer (AB; initial pH 4.5), and simulated intestinal fluid without added pancreatin (SIF; initial pH 6.8). Tween-20 was included at 0.05% v/v as a surfactant to aid in solubilizing test drugs. The final pH of the media with patiromer added at 25.2 g/L was as follows: SGF pH 3.0, AB pH 4.6, and SIF pH 5.9.

Binding studies were performed in a 10 ml volume in 16×100 mm borosilicate tubes, and incubated for 3 h at 37°C with end-over-end rotation at ~25 rpm. After incubation, patiromer was allowed to settle for 5 min; supernatants were withdrawn and passed through a 0.45 μm filter, collected by centrifugation, and transferred to chromatography vials for analysis. Control samples containing buffer and drug, but without patiromer, were subjected to the same experimental process. For 24 of the test drugs, a reversed phase high performance liquid chromatography method was used for analysis in the three test matrices. Atorvastatin and digoxin were measured using liquid chromatography-mass spectrometry methods, while lithium was analyzed using ion chromatography. All analytical methods were qualified to demonstrate specificity, linearity, accuracy and precision, and stability. During method qualification, we conducted a pretest of each drug in test media alone to assure no significant loss in recovery during the incubation or filtration steps. If there was not sufficient recovery compared to theoretical concentration, the drug could not be evaluated in that medium. The recovered drug in the presence or absence of patiromer was used to calculate percent recovery of test drug, and represents the geometric mean of 12 replicates.

Dose-response studies were performed using the same method across a range of test drug concentrations.

**Drug Structures and Properties**

A total of 121 computed molecular descriptors were considered in the development of the QSAR models, including electronic, steric, topological, and hydrophobic terms (Supplementary Table S1).

The molecular structure of each drug listed was downloaded from the Division of Specialized Information Services website of the National Laboratory of Medicine (http://chem.sis.nlm.nih.gov/chemidplus/) and processed to produce an appropriate three-dimensional representation with the LigPrep 3.0 application in Schrödinger suite, accessible from the Maestro interface (QikProp; Schrödinger, LLC; 2014). The LigPrep 3.0 program used the following criteria: neutral charge state, generate possible tautomers, generate conformers, force field: OPLS 2005. A final energy minimization was carried out with the OPLS_2005 force field, with implicit solvent (water).

Molecular properties were computed with several programs: various charged partial surface area terms were computed with the QikProp 3.9 program (using the –altclass option; QikProp; Schrödinger, LLC; 2014); ACD Labs logD 12.00 (Advanced Chemistry Development, Inc.; 2014); BioByte ClogP 4.9 (BioByte Corp); and an in-house program (polar version 1.1) (7). The polar program utilized the AM1 semi-empirical Hamiltonian to compute the molecular charges and molecular orbital energies. As some of the test compounds may be ionized
### Table 1  Physicochemical Properties of Test Compounds and In Vitro Patiromer Binding

| Name                | BCS Class | pKa     | LogP  | LogD pH 3.0, 4.5, 5.9 | Conc Used In Vitro (μg/mL) | SGF (pH 3) | Acetate Buffer (pH 4.5) | SIF (pH 5.9) |
|---------------------|-----------|---------|-------|-----------------------|---------------------------|------------|------------------------|--------------|
| Allopurinol         | III       | 9.18 A  | −0.3 (N) | −0.3 (all)            | 100                       | 85.7       | 90.1                   | 94.2         |
|                     |           | 12.12 A | 1.21 (A) | 0.21 (all)            |                           |            |                        |              |
| Amoxicillin         | III       | 2.60 A  | −0.02 (N) | 1.65                 | 500                       | ND a       | 99.2                   | 99.4         |
|                     |           | 7.35 B  | 2.19 (C) | 0.46                 |                           |            |                        |              |
|                     |           | 9.59 A  | 0.00    | 0.00                 |                           |            |                        |              |
| Apixaban            | III       | NA      | <1.40 (N) | <1.40 (all)          | 5                         | 75.6       | 97.3                   | 97.8         |
| Aspirin             | III       | 3.50 A  | 0.90 (N) | 0.78                 | 81                        | 100.7      | 99.8                   | 99.9         |
|                     |           |         | −0.14   | −1.50               |                           |            |                        |              |
| Atrorvastatin calcium | II       | 4.47 A  | 4.01 (N) | 3.99                 | 10                        | 91.2       | 93.3                   | 101.1        |
|                     |           | 1.04 (A) | 3.69   | 2.58               |                           |            |                        |              |
| Cephalexin          | III       | 2.56 A  | −1.05 (N) | −1.20                 | 250                       | 88.7       | 95                    | 104.4        |
|                     |           | 7.10 B  | 1.20    | −1.06               |                           |            |                        |              |
|                     |           |         | −1.08   | 0.125               |                           |            |                        |              |
| Digoxin             | II        | NA      | 1.64 (N) | 1.64 (all)          | 5                         | 72.9       | 96.5                   | 98.5         |
| Glipizide           | II        | 5.06 A  | 2.91 (N) | 2.91                 | 5                         | 77.9       | 100.7                  | 98.5         |
|                     |           |         | −0.45   | 2.82               |                           |            |                        |              |
|                     |           |         |         | 2.08               |                           |            |                        |              |
| Lisinopril          | III       | 1.63 A  | −0.51 (N) | −0.85                 | 5                         | 77.9       | 100.7                  | 98.5         |
|                     |           | 3.13 A  | 0.52    | −0.54               |                           |            |                        |              |
|                     |           | 7.13 B  | 0.52    | −0.54               |                           |            |                        |              |
|                     |           | 10.75 B | 0.52    | −0.54               |                           |            |                        |              |
| Phenytoin sodium    | II        | 8.18 A  | 2.43 (N) | 2.43 (all)          | 25                        | 83.4       | 90.2                   | 92.8         |
|                     |           |         | −0.09   | 2.43 (all)          |                           |            |                        |              |
| Riboflavin          | I         | 9.87 A  | −1.50 (C) | −1.50 (all)         | 1.2                       | 95.6       | ND b                   | 96.5         |
| Rivaroxaban         | II        | NA      | 1.43 (N) | 1.43 (all)          | 10                        | 71.9       | 92.9                   | 95.1         |
| Spironolactone      | II        | NA      | 2.53 (N) | 2.53 (all)          | 25                        | 78.7       | 98.6                   | 96.8         |
|                     |           |         |         | 25.3 (all)          |                           |            |                        |              |
| Valsartan           | II        | 3.73 A  | 3.98 (N) | 3.9                  | 40                        | 86.4       | 101.4                  | 98.0         |
|                     |           | 4.4 A   | 2.83    | 0.46               |                           |            |                        |              |

**No Significant Binding**

≥70% drug recovered (ie, ≤30% drug bound) in all tested buffers

| Name                | BCS Class | pKa     | LogP  | LogD pH 3.0, 4.5, 5.9 | Conc Used In Vitro (μg/mL) | SGF (pH 3) | Acetate Buffer (pH 4.5) | SIF (pH 5.9) |
|---------------------|-----------|---------|-------|-----------------------|---------------------------|------------|------------------------|--------------|
| Clopidogrel bisulfate | II       | 4.66 B  | 4.06 (N) | 2.40                 | 75                        | 66         | ND a                   | ND a         |
|                     |           | 0.95 (C) | 3.67   | 4.03               |                           |            |                        |              |
| Furosemide          | IV        | 3.62 A  | 2.20 (N) | 2.10                 | 20, 10 (SGF)              | 67.3       | 94.5                   | 79.1         |
|                     |           | 10.16 A | −0.82 (A) | 1.25               |                           |            |                        |              |
|                     |           |         | −0.03   | 1.25               |                           |            |                        |              |
| Lithium carbonate*  | I         | NA      | NA     | NA                  | 600                       | 93.3       | 88.8                   | 56.9         |
| Metformin HCl       | III       | 2.94 B  | −1.50 (N) | −1.50 (all)         | 500                       | 48.9       | 81.8                   | 80.2         |
|                     |           | 13.7 B  | 3.9     | 3.9                 |                           |            |                        |              |
|                     |           | 9.61 B  | 1.91 (N) | −4.70                 | 25                        | 71.7       | 85.9                   | 68.6         |
|                     |           |         | −3.20   | −1.80               |                           |            |                        |              |
| Metoprolol tartrate | I         | NA      | NA     | NA                  | 600                       | 93.3       | 88.8                   | 56.9         |
| Verapamil HCl       | I         | 8.95 B  | 4.20 (N) | 0.52                 | 120                       | 51.7       | 88.6                   | 77.9         |
|                     |           | 0.52 (C) | 0.59   | 0.59               |                           |            |                        |              |
|                     |           |         | 1.24   | 1.24               |                           |            |                        |              |
| Warfarin (R/S)      | II        | 4.94 A  | 3.25 (N) | 3.25                 | 2                         | 66.3       | 92.5                   | 97.3         |
|                     |           |         | −0.77   | 3.25               |                           |            |                        |              |

**Weak Binding**

45–70% drug recovered (30–55% drug bound) in one test media only
at various pH levels, logD values were computed \[\text{logD} = \text{logP} - \text{log}(1 + 10^{\text{pKa} - \text{pH}})\], at various pH values (pH = 1.2, 3.0, 4.5, 5.9). All statistics were performed with the R program 3.1.0 and standard statistical modules therein (8).

### QSPR Modeling

Step-wise linear regression was used to develop QSPR models describing properties driving drug-patiromer in vitro binding in each of the three test media used. For each drug evaluated by QSPR modeling, the mean geometric ratio of recovered drug with and without patiromer in each buffer was calculated and used in the subsequent regression analysis, along with the molecular properties shown in Supplementary Table S1.

Most of the molecular parameters used in model building were computed based on the neutral species, as required in QikProp. For this reason, lithium and thiamin were not included in the regression analysis. For factors that vary with pH (e.g., LogD, pKa), the relevant values were included in the modeling of patiromer binding at that pH. Levothyroxine was not included in the regression analysis because in vitro binding could not be measured due to precipitation of levothyroxine in the presence of the patiromer calcium counter-ion.

The \(R^2\) value was calculated for each QSPR equation. In order to assess the accuracy of each linear regression model, a leave-one-out cross-validation was performed and the results were reported as a \(Q^2\) value (9). In addition, \(p\)-values for coefficients in the QSPR equations were calculated.

### RESULTS

We selected 28 drugs to evaluate for binding to patiromer in vitro over a range of pH and ionic conditions intended to mimic the gut environment. Test drugs were initially selected based on relevance to the patiromer patient population and represented a chemically and functionally diverse group. The test panel included compounds with varied physicochemical properties from all four of the Biopharmaceutics Classification System (BCS)
drug classes (Table I). Drugs that might be more likely to interact with patiromer due to positive charge, basicity, or hydrophilicity were also included in the test panel, as were several drugs with a narrow therapeutic index, as it is particularly important to be able to control the exposure of these types of therapeutics.

Values for pKa, logD and logP and in vitro binding data at three different pHs were determined experimentally (Table I). To measure binding, each compound was co-incubated with patiromer using the highest single clinical dose of polymer and the minimum clinical dose of test drug. This approach is expected to maximize the availability of drug binding sites on patiromer and the ability to detect drug-patiromer interaction. A 3-h co-incubation time was selected, as that is anticipated to be the longest time that the polymer and the co-administered drug will routinely be in close contact prior to absorption of the co-administered drug. Stomach exposure (SGF conditions) is less than 3 h (10) and upper GI exposure (AB buffer conditions) is about 3 h (11,12). The majority of tested drugs have a Tmax of less than 3 h (4), and little drug will be present in the colon (SIF conditions). Following co-incubation, patiromer and any bound drug were removed by centrifugation and the remaining unbound (recovered) drug was measured in the supernatant.

As shown in Table I, 14 of the 28 drugs tested (50%) did not show significant binding to patiromer, which was defined as ≥70% of the drug being recovered in the supernatant following co-incubation. Thirteen other compounds showed significant binding to patiromer: 8 drugs were weak binders, with 30–55% of drug bound to patiromer in a single test condition; 5 were strong binders, with >55% of drug bound in multiple test conditions. Levothyroxine, a known calcium binder, (13) could not be tested as it precipitated in the presence of patiromer and its co-administered drug. Stomach exposure (SGF conditions). Following co-incubation, patiromer and any bound drug were removed by centrifugation and the remaining unbound (recovered) drug was measured in the supernatant.

We investigated whether the in vitro binding data could be used to generate a QSPR that might allow in silico prediction of the potential of an untested drug to bind to patiromer. As the in vitro binding of each drug was assessed at a single concentration, and that concentration depended on the clinically relevant dose for each drug, we sought to demonstrate that the resulting binding was not strongly dependent on the tested concentration of drug. Consequently, we conducted further in vitro testing of patiromer’s interaction with three of the strong binders, amiodipine besylate, quinidine gluconate and trimethoprim, across a range of drug concentrations to determine the impact of drug concentration on binding (Supplementary Figure S1). Binding to patiromer did not show strong concentration dependence across a clinically relevant dose range for the three drugs tested. Thus, despite the varied concentrations of drug used in the in vitro studies, the data were judged suitable to develop in silico models for patiromer-drug binding.

Having confirmed that the test panel included a well-balanced set of binding and nonbinding drugs, data from 25 of the original 28 compounds were used to build QSPR models of patiromer-drug binding in vitro. The data for patiromer binding to the test drugs reported in Table I do not suggest a simple relationship between in vitro binding and any single structural feature or physical property of the compounds, such as lipophilicity, charge, or polarity. To build predictive models, we measured or calculated 121 physical property descriptors for the drugs (Supplementary Table S1; see Wessel et al [7] for more on these descriptors) and applied step-wise linear regression with both forward and backward search selection to produce a model of patiromer-drug binding in each buffer. The resulting QSPR models were validated using the leave-one-out method, following an approach similar to that used by Walker et al. (2009) to define QSPR models for binding to colesevelam (5).

The QSPR model terms identified for patiromer-drug binding in vitro are given below and the corresponding coefficients and p values are reported in Table II.

### Table II Summary of QSPR Model Regression Coefficients and P-Values

| Model | Intercept | SAAA1 | IPeV | EA.eV | QPlogPw | X.noncon | X.amide |
|-------|-----------|-------|------|-------|---------|----------|--------|
| SGF   | −396.3906 (0.0000) | NA | 46.4826 (0.0000) | NA | 4.0192 (0.0005) | −2.1771 (0.0288) | −22.2272 (0.0659) |
| AB    | −189.9966 (0.0052) | 0.3818 (0.0001) | 26.5812 (0.0012) | −16.8010 (0.0274) | NA | −1.6017 (0.0070) | NA |
| SIF   | −294.4202 (0.0009) | 0.4371 (0.0002) | 36.8472 (0.0004) | −13.3460 (0.1402) | NA | −2.2171 (0.0036) | NA |

Values in parentheses represent p-values from the linear regression model; see definition of terms, below.

Coefficients:
- SAAA1, sum of surface area on acceptor atoms (oxygen, nitrogen) Å²
- IPeV, PM3 calculated ionization potential (negative of HOMO energy)
- EA.eV, PM3 calculated electron affinity (negative of LUMO energy)
- QPlogPw, QikProp predicted water/gas partition coefficient
- X.noncon, number of ring atoms not able to form conjugated aromatic systems (eg, sp³ C)
- X.amide, number of non-conjugated amide groups

AB, acetate buffer; NA, not applicable; QSPR, quantitative structure-property relationship; SGF, simulated gastric fluid; SIF, simulated intestinal fluid
In SGF buffer (pH 3.0), binding was best predicted by the physical parameters:

\[
\text{IP} \cdot \text{eV} + \text{QPlogPw} + X_{\text{noncon}} + X_{\text{amide}}
\]

where IP.eV is the ionization potential, QPlogPw is the predicted partition coefficient in water/gas, X.noncon is the number of ring atoms not able to form conjugated aromatic systems, and X.amide is the number of non-conjugated amide groups.

The QSPR models for binding in SIF (pH 4.6) and AB (pH 5.9) test media also incorporate the ionization potential and X.noncon terms. However, two other terms appear, yielding the equation:

\[
\text{SAAA1} + \text{IP} \cdot \text{eV} + X_{\text{noncon}} + \text{EA} \cdot \text{eV}
\]

where SAAA1 is the computed surface area of hydrogen bond acceptor atoms and EA.eV is electron affinity.

Predicted binding to patiromer was calculated for each drug using the relevant QSPR equation and compared to the experimentally observed values, as shown graphically in Fig. 2 and detailed in Supplementary Table SII. All of the models yielded a traditional \(R^2\) of ~0.7. A cross-validated \(Q^2\) value was generated using leave-one-out analysis. \(Q^2\) values of ~0.6 were obtained. An \(R^2\) of 0.7 implies that the variables in the model together account for ~70% of the variation in the binding to patiromer under the specified in vitro conditions. The remaining 30% variance is likely attributable to untested variables and to variability inherent in the assay system. The small difference between \(R^2\) and \(Q^2\) values (ie, \(R^2 - Q^2 < 0.3\)) suggests that our models are not over-fit and should be predictive for compounds that have not been included in the current study (14).

To further characterize the influence of the terms identified in the QSPR models on patiromer-drug binding in vitro, we compared the properties of the strong, weak, and non-binding compound groups identified earlier (Table III). The non-binding test compounds typically have multiple polar functional groups, such as cephalaxin and riboflavin; or acidic groups, such as valsartan. Drugs that bound patiromer in vitro tended to have fewer polar groups and were more lipophilic than the nonbinders. Weak binders of patiromer, such as clopidogrel or metoprolol, were neutral to weakly basic, with limited polar functionality. Strong patiromer binding was seen in vitro...
with drugs containing basic amines not balanced by a nearby polar group, such as cinacalcet.

Thus, in this manuscript, we have demonstrated that the QSPR models predicted \textit{in vitro} binding. However, as published previously, \textit{in vitro} binding was not predictive of \textit{in vivo} DDIs (4).

### DISCUSSION

A QSPR model has been used to illustrate an in silico approach to evaluate potential binding of drugs to polymer therapeutics. Such QSPR models can be developed based on a subset of possible interacting drugs, and can reveal the molecular characteristics most predictive of \textit{in vitro} binding to polymers, as evidenced by the close correlation between predicted and observed binding values.

The QSPR models developed for patiromer-drug binding \textit{in vitro} reflect interactions between multiple drug properties, rather than a univariate relationship to lipophilicity or charge (in contrast, lipophilicity [LogD] was identified as the major determinant of \textit{in vitro} binding to colesevelam [5]). For patiromer, ionization potential and availability of surface hydrogen bond acceptors were key factors over the physiological pH range of the gut. At the lowest pH tested (3.0), lipophilicity (QPlogPw) was also influential, but this factor was not predictive in matrices with higher pH values.

When test drugs were stratified based on the extent of binding to patiromer (strong, weak, or none), shared molecular characteristics emerged for each set. In general, non-binding test drugs had multiple polar functional groups. They included examples from multiple drug classes (eg, amoxicillin, glipizide, furosemide), and relatively small, highly polar compounds, such as allopurinol and warfarin. In particular, the inclusion of carboxylates and multiple hydroxyl groups appears to greatly decrease the likelihood of binding to patiromer.

#### Table III  Patiromer Binding \textit{In Vitro}, Molecular Properties Affecting Binding, and Observed Clinical DDI Results (4)

| Binding categories | Test drug  | Level of \textit{in vitro} interaction with patiromer | QSPR molecular properties | AUC reduced when co-administration (4) (lower bound of the 90% CI <80\%) |
|-------------------|------------|--------------------------------------------------|--------------------------|-------------------------------------------------|
| No binding        | Allopurinol Amoxicillin Apixaban Aspirin Atorvastatin Cephalaxin Digoxin Glipizide Lisinopril Phenytion Riboflavin Rivaroxaban Spironolactone Valisartern | <30\% drug bound in any test matrix | Non-binding compounds tend to be highly polar with multiple polar functional groups (eg, nitro, sulfonamide, etc.). Compounds with acidic groups also show no binding | Not tested: no binding in vitro |
| Weak binder      | Clopidogrel Furosemide Lithium Metformin Metoprolol Venpamol Warfarin (−R, −S) | 30–55\% bound in one test matrix | Weak \textit{in vitro} drug binding to patiromer begins to occur as the number of polar groups on the test drug decreases or its lipophilicity increases. Weak binders of patiromer tend to be neutral to weakly basic, with limited polar functionality, such as clopidogrel or metoprolol | Metformin, 1000 mg |
| Strong binder    | Amlodipine Cinacalcet Ciprofloxacin Levotheroxine** Thiamin* Trimethoprin Quinidine* | >55\% bound in two or three test matrices | The strongest \textit{in vitro} binding to patiromer is predicted to occur with drugs that contain basic amines that are not balanced by a polar functionality, eg, a carboxylate or cyano group or multiple amides, in close proximity to the basic group. | Ciprofloxacin, 500 mg Levothyroxine, 0.6 mg |

*In \textit{in vitro} binders not included in clinical study; **Not tested in \textit{in vitro} AUC, area under the plasma concentration–time curve from 0 to infinity; CI, confidence interval; DDI, drug-drug interaction; QSPR, quantitative structure-property relationship
Those drugs that did bind patiromer in vitro tended to have fewer polar groups and were more lipophilic than the nonbinders. The weak binders were generally neutral to weakly basic, with limited polar functionality, as exemplified by clopidogrel or metoprolol. The strongest in vitro binding to patiromer is predicted to occur with drugs that contain basic amines that are not balanced by a polar functionality, eg, a carboxylate or cyano group or multiple amides, in close proximity to the basic group.

It is important to note, however, that while the QSPr models for patiromer have predictive value for in vitro binding, additional factors, such as drug dissolution, absorption and binding to other gut contents, intervene in vivo to determine whether a significant DDI will occur. Our findings (4) and those of Walker et al. (5) both suggest that in vitro polymer-drug binding studies tend to over-predict clinically meaningful DDIs. In the case of patiromer, only 3 of 12 drugs that bound patiromer in vitro showed a potentially clinically relevant pharmacokinetics (PK) change, defined as 80–125% of the 90% confidence interval for the area under the plasma concentration–time curve from 0 to infinity (AUC). No clinically relevant DDIs were observed when test drug and patiromer were given 3 h apart (4). Of the four strong in vitro patiromer binders that were tested clinically, only ciprofloxacin showed a decrease in systemic absorption when administered together with patiromer. Because both ciprofloxacin and levothyroxine bind calcium, the effects on PK observed upon administration of either drug together with patiromer may reflect binding to patiromer’s calcium counter-ion, rather than to the anion itself.

The data generated for metformin are also illustrative of the principle that other factors beyond in vitro binding influence the potential for clinical DDIs with nonabsorbable polymeric drugs. Metformin is a weak binder in vitro, but also showed a moderate reduction in AUC in healthy volunteers when co-administered with patiromer. Metformin has low permeability and its uptake is transporter-mediated, thus saturable (15). Interaction with patiromer may compete with transporter-mediated absorption and, in the presence of patiromer, a greater proportion of the drug may fail to bind to transporters during the gut transit period, leading to a reduced AUC.

CONCLUSION

The potential for polymeric therapeutics to reduce the bioavailability of co-administered drugs is limited to binding that may occur in the lumen of the gastrointestinal tract, because the polymers are not systemically absorbed. In this paper we demonstrate that an in silico QSPr approach can be used to characterize the drivers of in vitro binding and has the potential to predict which drugs are more likely to show a binding interaction. Thus, in vitro binding combined with QSPr can be used proactively to narrow the subset of drugs that are tested clinically for drug interactions with polymers.

ACKNOWLEDGMENTS AND DISCLOSURES

This study was sponsored by Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, California. Medical writing assistance was provided by Mary Lee MacKichan, PhD; editorial support was provided by Impact Communication Partners, Inc. All authors reviewed and approved the final version of the manuscript. C.T.B, A.M., F.L., D.C., Y.M., M.M., D. Maclean, and S.H. are employees of Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA. D. Madsen, W.S., and D. Matthews, were employees of Relypsa, Inc., at the time of the study. J.F.B. is an employee of Array Biopharma Inc., Boulder, CO.

Funding This study was funded by Relypsa, Inc. Medical writing assistance and editorial support was funded by Relypsa, Inc.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

REFERENCES

1. Connor EF, Lees I, Maclean D. Polymers as drugs—advances in therapeutic applications of polymer binding agents. J Polymer Science Part A: Polymer Chemistry. 2017;55(18):3146–57.
2. Relypsa Inc. Veltassa (patiromer) full prescribing information. 2016.
3. Li L, Harrison SD, Cope MJ, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther. 2016;21(5):436–65.
4. Lesko LJ, Oliffin E, Brew CT, et al. Evaluation of the potential for drug interactions with patiromer in healthy volunteers. J Cardiovasc Pharmacol Ther. 2017;22(5):434–46.
5. Walker JR, Brown K, Rohatagi S, et al. Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colestevam (Welchol). J Clin Pharmacol. 2009;49(10):1185–95.
6. Schiller C, Frohlich CP, Giessmann T, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2005;22(10):971–9.
7. Wessel MD, Jurs PC, Tolan JW, Muskal SM. Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sci. 1998;38(4):726–35.
8. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2014. Available from: http://www.R-project.org/

9. Venables WN, Ripley BD. Modern applied statistics with S. 4th ed. New York: Springer-Verlag; 2002.

10. Camilleri M. Drug–resin drug interactions in patients with delayed gastric emptying: what is optimal time window for drug administration. Neurogastroenterol Motil. 2016;28(8):1268–71.

11. Thelen K, Coboeken K, Willmann S, et al. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solution. J Pharm Sci. 2011;100(12):5324–45.

12. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut. 1986;27(8):886–92.

13. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283(21):2822–5.

14. Veerasamy R, Subramaniam DK, Chean OC, Ying NM. Designing hypothesis of substituted benzoxazinones as HIV-1 reverse transcriptase inhibitors: QSAR approach. J Enzyme Inhib Med Chem. 2012;27(5):693–707.

15. Personal communication, 2016. Dr. Madabushi, Office of Clinical Pharmacology, FDA.